Search | Clinical Trials Finder

Conditions: Volunteer, Attention Deficit Hyperactivity Disorder
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: ADHD
Interventions: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet; Drug
Lead sponsor: Cingulate Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 38
States / cities: Beverly Hills, California • Garden Grove, California • Los Alamitos, California + 33 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Meta Quest 3 VR Headset with noise cancelling headphones; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 25 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • New Brunswick, New Jersey

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: CTN XR (TBM), CTN SR, CTN XR (Clin); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Lenexa, Kansas • Millcreek, Utah

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Lisdexamfetamine; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Years to 30 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: ADHD, Cannabis Use Disorder
Interventions: Delayed-release, extended-release methylphenidate, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 26 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
Interventions: Centanafadine, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 46
States / cities: Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 41 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: methylphenidate, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 21 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1986 – 1994
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: PRC-063 25 mg, Placebo, PRC-063 35 mg, PRC-063 45 mg, PRC-063 55 mg, PRC-063 70 mg, PRC-063 85 mg, PRC-063 100 mg; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Newport Beach, California • Las Vegas, Nevada

Conditions: Attention Deficit-Hyperactivity
Interventions: MYDAYIS, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Adult Participants
Interventions: Centanafadine; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: ADHD, Attention Deficit Hyperactivity Disorder
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: ADHD
Interventions: methylphenidate HCl (Concerta), Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Adult Attention Deficit Hyperactivity Disorder
Interventions: Dasotraline; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 65
States / cities: Beverly Hills, California • Encino, California • Escondido, California + 52 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: UC-A, UC-N; Device
Lead sponsor: Think Now Incorporated; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Berkeley, California • Los Angeles, California

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Lisdexamfetamine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: ADHD NOS
Interventions: Strattera (atomoxetine); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: ADHD
Interventions: PRC-063 oral capsules, Placebo oral capsules; Drug
Lead sponsor: Purdue Pharma, Canada; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more

Conditions: ADHD Specifically With Executive Function Impairment
Interventions: SPD489, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 39
States / cities: Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 34 more

Conditions: Attention Deficit Disorder With Hyperactivity (ADHD)
Interventions: Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (Sham TMS); Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Autism Spectrum Disorder
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: IR Viloxazine, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Bradenton, Florida • Libertyville, Illinois • Owensboro, Kentucky + 1 more

Conditions: Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Centanafadine SR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Culver City, California

Search by objective public record fields.

PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)

CTx-1301 Comparative Bioavailability Study

Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

R61/33 - VR Study Phase 4

A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels

Lisdexamfetamine's Effect In ADHD in the Brain and Cognition

Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With ADHD and Cannabis Use Disorder

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

Further Studies of Attention Deficit Disorder - Residual Type (RT)

PRC-063 in an ADULT Workplace Environment

Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening

Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects

A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder

A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder

Open-label Safety Study in Adults With ADHD

Assessing Mobile Apps for Adult ADHD

Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults

Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Transcranial Magnetic Stimulation for Attention Deficit/Hyperactivity Disorder (ADHD)

Autism Spectrum Disorders (ASD) Driving Study

Evaluation of Immediate-Release Viloxazine in Adults With ADHD

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder